Hook and thesis
Verisk is a classic software-like analytics business: recurring contracts, sticky customers (primarily insurers), and high free cash flow. The stock has been punished recently - it hit a 52-week low of $164.60 on 02/12/2026 - but the business fundamentals and cash generation remain intact. With the company refinancing borrowings tied to accelerated share repurchases and printing $1.19B in free cash flow, now is a tactical window to buy into the recovery with clearly defined risk.
This is a trade idea, not a proclamation that the company is without headwinds. I think Verisk is a long with a defined entry and stop because (1) valuation multiples have compressed to levels that understate the resilience of subscription analytics, (2) liquidity and technicals look constructive near $207.61, and (3) near-term balance sheet actions remove a cloud on financial flexibility.
What Verisk does and why the market should care
Verisk provides data, predictive analytics and decision-support technology to insurers and other risk-bearing businesses. Its core Insurance segment supplies tools for rating, underwriting, claims, catastrophe modeling and fraud detection, typically on subscription or long-term agreements. For companies that price risk, detect fraud and manage claims, access to accurate, modelled data is mission-critical.
Why the market should care: the business benefits from sticky contract revenue, secular tailwinds in insurance analytics and growing demand for AI-enabled risk intelligence. The insurance analytics market is expanding rapidly and enterprise spending on data intelligence is growing; that structural setup favors incumbents that own domain-specific models and datasets.
Key numbers that support the thesis
- Current price: $207.61; market capitalization roughly $28.6B and enterprise value about $30.8B.
- Reported free cash flow of $1,191,900,000 - cash generation that supports dividends, buybacks and debt service.
- Earnings per share around $6.52 and a P/E in the low 30s (roughly 31.1), signaling a premium multiple for a recurring-revenue business but lower than the levels seen near last years peak.
- Valuation multiples: EV/sales ~10.02, EV/EBITDA ~18.24, price/sales ~9.19 and price/book ~92.97 - the high price/book reflects intangible-heavy, high-return economics rather than asset-based value.
- Dividend yield about 0.89% with an upcoming ex-dividend date on 03/13/2026 and payable date 03/31/2026 - modest yield but consistent with a growth/cash-conversion profile.
- Technicals: the stock sits near the 50-day average (~$207.54) with an RSI around 60.9 and a bullish MACD histogram, suggesting constructive momentum after recent weakness.
Why the recent weakness happened
Verisk has been sensitive to top-line execution. Q3 2025 results (reported 10/29/2025) included a revenue miss and a reduced full-year revenue guide, which triggered a >10% sell-off. In early 2026 the stock made a new near-term low at $164.60 (02/12/2026) as markets punished growth disappointments and feared leverage from ASR-funded borrowings.
Management has acted: on 02/24/2026 the company priced $500M of 4.450% senior notes due 2031 and $500M of 5.125% senior notes due 2036 to repay borrowings from a term loan and revolving facility that had funded accelerated share repurchases. That refinancing tidies the balance sheet and replaces short-term bank debt tied to ASRs with longer-dated public debt.
Valuation framing
At a market cap near $28.6B and EV ~$30.8B, Verisk is being priced for steady, not spectacular, growth. The company trades around 31x reported EPS and about 18x EV/EBITDA. Those multiples reflect a premium for predictable revenue and high margins, but they also leave little room for repeat guidance misses.
Two ways to look at valuation:
- Relative to high-growth pure software names, Verisks multiples look moderate because its growth is slower but steadier; compared to low-growth industrials, its multiples look expensive because the business is services/analytics-driven and generates sustainable free cash flow.
- Practically, a recovery in organic growth rates or reacceleration in cross-sell (fraud detection, cyber risk, carbon claims tools) could justify multiple expansion from low-30s P/E into the mid-30s, adding meaningful upside even without dramatic top-line surprises.
Catalysts to drive the trade
- Balance-sheet cleanup: Closing the note offering on 02/26/2026 and repaying bank borrowings tied to ASRs will remove refinancing risk and improve interest-cost visibility.
- AI and analytics tailwinds: Continued demand for insurance analytics, fraud detection and cyber risk tools (e.g., expanded KYND collaboration) supports higher subscription spend.
- Operational execution: A return to consistent revenue growth and margin stability in upcoming quarterly reports would reduce multiple compression and invite re-rating.
- Shareholder returns: the combination of manageable leverage and strong free cash flow keeps buyback and dividend optionality on the table; any renewal or acceleration of buybacks after the refinance would be a positive sign.
Trade plan (actionable)
My plan is a directional long with explicit risk controls. This is for investors willing to hold a position through a full recovery process.
- Entry: Buy at $207.61 (current price) or on a pullback to $200.00 if you prefer a tighter entry - I am specifying $207.61 as the actionable trigger for this write-up.
- Stop loss: $191.00 - place a hard stop below the recent short-term technical support band and below the 50-day EMA cushion; a break below $191 would indicate a failure to stabilize and could reopen the downside toward the 02/12/2026 low.
- Target: $270.00 - this reflects a modest multiple re-rating and modest revenue/margin improvement; it is a realistic multi-month outcome if catalysts materialize.
- Time horizon: Long term (180 trading days). I expect the trade to need time for the balance-sheet story to settle, for revenue trends to re-accelerate, and for multiple expansion to occur. If catalysts arrive faster, consider taking partial gains earlier. If guidance remains soft at the next quarter, reevaluate.
Why 180 trading days? The refinancing closes the near-term funding gap but meaningful re-rating requires at least one or two quarters of evidence that revenue and bookings are stabilizing. Operating cadence in insurance analytics can be seasonal and multiyear, so patience is rewarded.
Risk framework - what can go wrong
- Operational execution risk: If Verisk misses revenue or bookings again, the market will reprice the stock lower. The company already saw a revenue-guidance cut in Q3 2025 that produced a >10% decline.
- Multiple compression: With a P/E in the low 30s and EV/EBITDA ~18.2, the stock leaves limited margin for error. Even small earnings misses can compress the multiple materially.
- Macroeconomic / catastrophe risk: Increasing insured losses from climate-related catastrophes could hurt insurer profitability and, by extension, budgets for analytics spend, or create volatility in Verisks modeled-loss products.
- Interest-rate and credit risk: The new notes (4.450% and 5.125%) increase fixed obligations; broader rate volatility or higher funding costs could squeeze free cash flow available for buybacks or M&A.
- Competition and technology risk: Fast-moving AI entrants and analytics startups could win share for specific point solutions (claims automation, agentic analytics), putting pressure on growth and pricing.
Counterargument: One could reasonably argue this is a value trap. Multiples are still high on absolute terms (price/book ~93) and the company has shown it can miss revenue targets; if growth stalls again, the company could struggle to justify the current price and any buybacks funded through leverage become less attractive.
That counterargument is valid and why I insist on a strict stop. This trade is conditional on evidence that management has stabilized revenue and that the financing moves reduce balance-sheet risk.
What would change my mind
- Negative trigger: A miss in the next two quarterly reports on both revenue and bookings would invalidate the thesis and likely push me to a full exit.
- Positive trigger: Clear sequential improvement in revenue, better-than-expected margins or reaccelerated cross-sell that drives upward guidance would prompt me to add to the position and raise the target above $270.
Conclusion
Verisk is a durable analytics franchise with strong cash generation and a structural market tailwind in insurance analytics and risk intelligence. Recent drawdowns and a necessary refinancing created an opportunity to buy with defined downside protection. The trade is not without risk: multiples are not cheap and execution matters. For disciplined investors comfortable with a 180 trading-day horizon, buying near $207.61 with a stop at $191 and a target of $270 offers an attractive risk/reward if the company demonstrates renewed top-line stability and the refinancing reduces balance-sheet overhang.
Trade summary (quick)
- Direction: Long
- Entry: $207.61
- Stop: $191.00
- Target: $270.00
- Horizon: Long term (180 trading days)